Treatment-induced stress syndromes

Medical Hypotheses

Volumn 74, Issue 5, 2010, Pages 764-768

  Healy, David ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; DIAZEPAM; METHYLPHENIDATE; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR;

CLINICAL RESEARCH; DETOXIFICATION; DRUG ABUSE; DRUG DEPENDENCE; DRUG WITHDRAWAL; EDITORIAL; HUMAN; MENTAL STRESS; WITHDRAWAL SYNDROME;

ANTIPSYCHOTIC AGENTS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; SEROTONIN UPTAKE INHIBITORS; STRESS, PSYCHOLOGICAL; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 77950958515     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2010.01.038     Document Type: Editorial

References (21)

1. Aldhous P. Prescription: sobriety. New Scientist, 9th Jan; 2010. p. 40-3.
2. American Psychiatric Association Task force on benzodiazepine in dependence, benzodiazepine dependence, toxicity and abuse 1990, APA, Washington, DC.
3. Battegay R. Drug dependence as a criterion for differentiation of psychotropic drugs. Compr Psychiat 1966, 7:501-509.
4. Bury M., Gabe J. Tranquillisers and health care in crisis. Soc Sci Med 1991, 32:449-454.
5. Coupland N.J., Bell C.J., Potokar J.P. Serotonin reuptake inhibitor withdrawal. J Clin Psychopharm 1996, 16:356-362.
6. Fava G. Holding on: depression, sensitization by antidepressant drugs, and the prodigal experts. Psychother Psychosom 1995, 64:57-61.
7. Fitzgerald K, Healy D. Dystonias and dyskinesias of the jaw following the use of SSRIs. Hum Psychopharm 1995.
8. Gaskell D. Drugs against drugs. Chem Br 1998, 34(12):27-32.
9. Gilbert P.L., Harris J., McAdams L.A., Jeste D.V. Neuroleptic withdrawal in schizophrenic patients. Arch Gen Psychiat 1995, 52:173-188. With commentaries by Baldessarini R, Viguera A, Carpenter W, Taminga C, Greden J, Tandon R, Meltzer H, Nuechterlein K, Wyatt R, et al.
10. Healy D. The creation of psychopharmacology 2002, Harvard U Press, Cambridge, MA.
11. Healy D., Tranter R. Pharmacologic stress diathesis syndromes. J Psychopharmacol 1999, 13:287-299.
12. Healy D., Mangin D., Mintzes B. The ethics of randomized placebo controlled trials of antidepressants with pregnant women. Int J Risk Safety Med 2010.
13. Hollister L. From hypertension to psychopharmacology: a serendipitous career. The psychopharmacologists 1998, vol. 2:215-235. Chapman and Hall, London.
14. Kramer J.C., Kline D.F., Fink M. Withdrawal symptoms following discontinuation of imipramine therapy. Am J Psychiatry 1961, 118:549-550.
15. Mann A.M., MacPherson A.S. Clinical experience with imipramine (G22355) in the treatment of depression. Can Psychiatric Assoc J 1959, 4:38-47.
16. Nutt D.J. Addiction, brain mechanisms and their treatment implications. Lancet 1996, 346:31-36.
17. Temple R. Psychopharmacological drugs advisory committee meeting on pediatric antidepressant suicidality; 2004 [comments at February 2, 2004]. http://www.fda.gov/ohrms/dockets/ac/04/transcripts/4006T1.pdf.
18. Tohen M., Calabrese J.R., Sachs G., et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry 2006, 163:247-256.
19. Tranter R., Healy D. Neuroleptic discontinuation syndromes. J Psychopharmacol 1998.
20. Whitaker R. Anatomy of an epidemic 2010, Crown Publishers, New York.
21. World Health Organisation. Expert committee on dependence producing drugs, 14th report, WHO Techn Rep Cir 312; 1965.